We are live on ! Find out more
NCM

Nantahala Capital Management Portfolio holdings

AUM $2.72B
1-Year Est. Return 121.58%
This Fund
S&P 500
This Quarter Est. Return
+15.96%
1 Year Est. Return
+121.58%
3 Year Est. Return
+308.64%
5 Year Est. Return
+308.9%
10 Year Est. Return
+2,888.73%
AUM
$2.33B
AUM Growth
+$352M
Cap. Flow
+$348M
Cap. Flow %
14.93%
Top 10 Hldgs %
55.33%
Holding
157
New
17
Increased
46
Reduced
30
Closed
20

Sector Composition

Rank Sector Weight
1 Healthcare 38.07%
2 Consumer Discretionary 9.17%
3 Communication Services 4.02%
4 Financials 3.76%
5 Industrials 2.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
THRD
76
DELISTED
Third Harmonic Bio
THRD
$5.16M 0.22%
+501,000
New +$6.24M
ANEB
77
DELISTED
Anebulo Pharmaceuticals
ANEB
$5.1M 0.22%
3,036,325
+2,525,252
+494% +$4.16M
XTNT icon
78
Xtant Medical Holdings
XTNT
$62.6M
$5.05M 0.22%
11,394,000
APYX icon
79
Apyx Medical
APYX
$146M
$5.01M 0.22%
+3,169,800
New +$4.43M
LXRX icon
80
Lexicon Pharmaceuticals
LXRX
$1.07B
$4.88M 0.21%
6,604,150
+4,300,000
+187% +$5.18M
THTX
81
DELISTED
Theratechnologies
THTX
$4.85M 0.21%
2,682,228
NNBR icon
82
NN Inc
NNBR
$300M
$4.77M 0.2%
1,458,416
ELDN icon
83
Eledon Pharmaceuticals
ELDN
$284M
$4.73M 0.2%
1,147,946
+547,946
+91% +$2.16M
EYPT icon
84
EyePoint Inc
EYPT
$1.13B
$4.47M 0.19%
+600,000
New +$5.58M
NSPR icon
85
InspireMD
NSPR
$37.5M
$4.4M 0.19%
1,674,565
-535,028
-24% -$1.44M
DHX icon
86
DHI Group
DHX
$158M
$4.21M 0.18%
2,376,606
IMTX icon
87
Immatics
IMTX
$1.33B
$4.12M 0.18%
578,856
-46,803
-7% -$402K
GAIA icon
88
Gaia
GAIA
$48.1M
$4.11M 0.18%
915,029
GPCR icon
89
CALL
Structure Therapeutics
GPCR
$3.82B
$4.07M 0.17%
+150,000
New +$5.32M
KROS icon
90
CALL
Keros Therapeutics
KROS
$212M
$3.96M 0.17%
+250,000
New +$13M
ZYXI
91
DELISTED
Zynex
ZYXI
$3.92M 0.17%
490,000
RDI icon
92
Reading International Class A
RDI
$35.2M
$3.78M 0.16%
2,864,046
-372,451
-12% -$550K
CMPS
93
Compass Pathways
CMPS
$1.78B
$3.78M 0.16%
1,000,000
+800,000
+400% +$4.06M
OCUL icon
94
Ocular Therapeutix
OCUL
$2.03B
$3.74M 0.16%
437,728
-262,272
-37% -$2.56M
QURE icon
95
CALL
uniQure
QURE
$3.2B
$3.55M 0.15%
201,000
SCPH
96
DELISTED
scPharmaceuticals
SCPH
$3.54M 0.15%
1,000,000
+250,000
+33% +$958K
MIST icon
97
Milestone Pharmaceuticals
MIST
$157M
$3.41M 0.15%
1,445,264
-304,736
-17% -$523K
SRL icon
98
Scully Royalty
SRL
$89.4M
$3.41M 0.15%
368,596
+129,399
+54% +$985K
CZR icon
99
Caesars Entertainment
CZR
$6.13B
$3.34M 0.14%
+100,000
New +$3.96M
PVLA
100
Palvella Therapeutics
PVLA
$2.19B
$3M 0.13%
+250,062
New +$3.93M

Similar funds

Nantahala Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Nantahala Capital Management held 157 positions worth $2.33B, up 18% from $1.98B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Nantahala Capital Management deployed $348M of net new capital in Q4 2024, opening 17 new positions and adding to 46 existing holdings. Its largest new stake was Service Properties Trust: 1,618,380 shares worth $20.6M.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 41% a quarter earlier, followed by Consumer Discretionary and Communication Services.

On the sell side, the largest reduction was Establishment Labs, an estimated $30.7M trimmed.

  • Nantahala Capital Management's largest Q4 2024 buy was Service Properties Trust: 1,618,380 shares worth $20.6M.
  • Nantahala Capital Management added most to Hilton Grand Vacations in Q4 2024, an estimated $38.8M increase.
  • Nantahala Capital Management's biggest Q4 2024 reduction was Establishment Labs, cutting an estimated $30.7M.
  • Nantahala Capital Management fully exited PowerSchool Holdings, Inc. in Q4 2024, selling an estimated $13.3M.
  • Nantahala Capital Management's ten largest holdings make up 55% of its $2.33B portfolio in Q4 2024.
  • Nantahala Capital Management opened 17 new positions and closed 20 in Q4 2024.
  • Nantahala Capital Management's portfolio value rose 18% quarter-over-quarter to $2.33B.

Based on Nantahala Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.